Vista Capital Partners Inc. acquired a new position in Stryker Corporation (NYSE:SYK – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 19,405 shares of the medical technology company’s stock, valued at approximately $5,344,000. Stryker accounts for approximately 0.5% of Vista Capital Partners Inc.’s investment portfolio, making the stock its 15th biggest holding.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Moors & Cabot Inc. grew its stake in shares of Stryker by 28.3% in the third quarter. Moors & Cabot Inc. now owns 11,524 shares of the medical technology company’s stock worth $3,174,000 after acquiring an additional 2,539 shares during the last quarter. Compass Capital Management Inc. increased its holdings in shares of Stryker by 5.0% during the third quarter. Compass Capital Management Inc. now owns 168,441 shares of the medical technology company’s stock valued at $46,387,000 after acquiring an additional 7,962 shares in the last quarter. Marble Harbor Investment Counsel LLC increased its holdings in shares of Stryker by 3.9% during the third quarter. Marble Harbor Investment Counsel LLC now owns 29,932 shares of the medical technology company’s stock valued at $8,243,000 after acquiring an additional 1,114 shares in the last quarter. Eurizon Capital SGR S.p.A. raised its position in shares of Stryker by 16.3% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 107,386 shares of the medical technology company’s stock worth $29,587,000 after purchasing an additional 15,048 shares during the last quarter. Finally, Nikulski Financial Inc. raised its position in shares of Stryker by 6.1% in the 3rd quarter. Nikulski Financial Inc. now owns 8,762 shares of the medical technology company’s stock worth $2,413,000 after purchasing an additional 502 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.
Stryker Stock Down 0.2%
Stryker stock opened at $309.05 on Monday. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $389.33. The stock has a fifty day simple moving average of $292.30 and a two-hundred day simple moving average of $322.60. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The firm has a market cap of $117.65 billion, a price-to-earnings ratio of 32.91, a PEG ratio of 2.13 and a beta of 0.78.
Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). The business had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.74%. The company’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same period in the previous year, the company earned $3.19 earnings per share. Equities analysts predict that Stryker Corporation will post 14.85 EPS for the current fiscal year.
Insider Buying and Selling
In other news, insider Debra King sold 826 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 550,000 shares of the business’s stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $325.32, for a total transaction of $178,926,000.00. Following the transaction, the director directly owned 1,701,375 shares of the company’s stock, valued at $553,491,315. The trade was a 24.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 901,267 shares of company stock worth $297,123,701. 4.60% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
Several analysts recently commented on SYK shares. JPMorgan Chase & Co. cut their price objective on shares of Stryker from $350.00 to $340.00 and set an “overweight” rating on the stock in a research report on Friday, October 30th. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Citizens Jmp decreased their target price on shares of Stryker from $400.00 to $390.00 and set a “market outperform” rating for the company in a report on Friday, October 30th. BTIG Research dropped their target price on shares of Stryker from $316.00 to $304.00 and set a “buy” rating on the stock in a research note on Friday, October 30th. Finally, Rothschild & Co Redburn dropped their target price on shares of Stryker from $360.00 to $336.00 in a research note on Monday, November 2nd. Twenty-one analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $342.19.
About Stryker
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Further Reading
- Five stocks we like better than Stryker
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
